PDS Biotechnology (NASDAQ:PDSB – Get Free Report) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.
Several other research analysts have also recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $21.00 price objective on shares of PDS Biotechnology in a research note on Thursday, October 24th. Alliance Global Partners upgraded PDS Biotechnology to a “strong-buy” rating in a report on Wednesday, August 21st. One analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $14.25.
View Our Latest Stock Analysis on PDSB
PDS Biotechnology Stock Up 0.3 %
PDS Biotechnology (NASDAQ:PDSB – Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.08. During the same quarter in the previous year, the firm earned ($0.37) earnings per share. Equities research analysts expect that PDS Biotechnology will post -1.24 earnings per share for the current year.
Hedge Funds Weigh In On PDS Biotechnology
A number of hedge funds and other institutional investors have recently modified their holdings of PDSB. Vanguard Group Inc. raised its stake in PDS Biotechnology by 5.5% in the first quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock worth $6,288,000 after buying an additional 82,135 shares in the last quarter. Blair William & Co. IL increased its holdings in shares of PDS Biotechnology by 204.4% in the 2nd quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock valued at $357,000 after acquiring an additional 81,743 shares during the period. Cubist Systematic Strategies LLC bought a new position in shares of PDS Biotechnology in the 2nd quarter worth $146,000. Squarepoint Ops LLC purchased a new stake in shares of PDS Biotechnology during the 2nd quarter worth $120,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in PDS Biotechnology during the second quarter valued at about $115,000. 26.84% of the stock is currently owned by institutional investors.
PDS Biotechnology Company Profile
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.
Read More
- Five stocks we like better than PDS Biotechnology
- Using the MarketBeat Stock Split Calculator
- Dot Ai IPO: CEO Ed Nabrotzky Shares Vision for Logistics Future
- What is Forex and How Does it Work?
- The Hottest Markets to Watch After the Fed’s 25 Bps Rate Cut
- What is the S&P/TSX Index?
- The Top 5 Performing S&P 500 Stocks YTD in 2024
Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.